ACTU

Business Context and Reporting Period

Company: Actuate Therapeutics, Inc. (ACTU)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: Actuate is a clinical-stage biopharmaceutical company developing elraglusib, a small molecule inhibitor of glycogen synthase kinase-3 (GSK-3), for the treatment of cancers including metastatic pancreatic ductal adenocarcinoma (mPDAC) and Ewing sarcoma. The company has no approved products and has not generated any revenue from product sales since inception.

Key Financial Metrics

Material Changes vs. Prior Period

• Initial Public Offering (IPO): The company completed its IPO on August 14, 2024, and the overallotment option on September 12, 2024. It issued 3,220,000 shares at $8.00 per share, receiving net proceeds of approximately $22 million. This significantly increased cash balances from $2.96 million at year-end 2023 to $13.52 million at September 30, 2024.
• Capital Structure Conversion: Upon the IPO closing, all Redeemable Convertible Preferred Stock ($94.18 million liquidation value) and Related Party Convertible Notes ($5.5 million principal) converted into common stock. Consequently, the balance sheet now reflects positive stockholders' equity of $5.36 million, compared to a deficit of $(99.63) million at December 31, 2023.
• Operating Expenses:
  • Q3 Comparison: Total operating expenses decreased by $1.08 million to $5.39 million. Research and Development (R&D) expenses dropped $2.0 million primarily due to fewer patients on treatment in the Phase 2 mPDAC trial and reduced preclinical studies. General and Administrative (G&A) expenses increased $0.92 million due to higher personnel costs (including stock-based compensation for new hires) and public company compliance costs.
  • YTD Comparison: Total operating expenses increased by $1.24 million to $18.60 million. R&D expenses were relatively flat, while G&A expenses increased $1.32 million driven by professional fees (search firm, legal, audit) and stock-based compensation related to the IPO.
• Non-Cash Items: The YTD 2024 net loss includes a $2.19 million non-cash loss from the change in fair value of related party convertible notes and a $0.4 million loss on issuance of those notes, offset by a $0.34 million gain on the settlement of warrants.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for twelve months from the issuance date. Despite the IPO proceeds, the company estimates its cash will not satisfy operational and capital requirements through that period. Additional financing will be required.
• Outlook: The company expects to continue incurring significant operating losses as it advances elraglusib through clinical trials (Phase 2 in mPDAC and Phase 1/2 in pediatric malignancies) and prepares for potential commercialization. Expenses are expected to increase substantially.
• Unusual Items:
  • Reverse Stock Split: A 1-for-1.8 reverse stock split was effected on June 7, 2024. All share and per-share data in the filing have been adjusted retrospectively.
  • Related Party Transactions: The company issued $5.5 million in convertible notes to a related party (Bios Clinical Opportunity Fund, LP) in early 2024, which converted to equity upon the IPO.
• Risks:
  • Capital Requirements: Failure to raise additional capital could force the company to delay, limit, or terminate development programs.
  • Clinical Development: Success depends entirely on elraglusib. Delays in enrollment, adverse safety events, or failure to meet efficacy endpoints could materially harm the business.
  • Supply Chain: The drug substance manufacturer is located in China, creating potential geopolitical and supply chain risks.
  • Internal Controls: A material weakness in internal control over financial reporting was identified in 2023 regarding the accrual of clinical trial expenses. Remediation procedures have been implemented.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for when current cash reserves ($13.5 million) will be exhausted and the status of any planned follow-on financing.
• Clinical Trial Progress: Confirm enrollment rates and interim data readouts for the Actuate-1801 (mPDAC) and Actuate-1902 (pediatric) trials.
• Manufacturing Dependencies: Assess the risks associated with the single-source drug substance manufacturer in China and any contingency plans for supply chain disruption.
• Equity Dilution: Review the impact of the 180-day lock-up expiration on share supply and potential future dilution from the 2024 Stock Incentive Plan (2.4 million shares available for grant).
• Internal Controls: Monitor the effectiveness of remediation efforts for the previously identified material weakness in financial reporting.